Fukuoka, Japan/New York, United States – July 1st 2025 – FELIQS Corporation (“FELIQS”), a biotechnology company developing first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases, today announced the successful completion of a $...